Company Information & Drug Savings for Viela Bio Medications

Viela Bio, acquired by Horizon Therapeutics (now Amgen), developed treatments for autoimmune and inflammatory diseases. The company created Uplizna (inebilizumab), an anti-CD19 therapy for neuromyelitis optica spectrum disorder (NMOSD). Viela’s innovative immunology approach continues advancing treatments for rare autoimmune conditions.

How to contact Viela Bio

Address

One MedImmune Way, Gaithersburg, MD 20878

Browse medications manufactured by Viela Bio